logo
logo

Noema Pharma Appoints Michael Samar As Chief Financial Officer and Volker Knappertz As Executive Vice President of Research and Development

Jan 08, 2025•7 months ago

Position

Vice President Of Research And Development

Company

Noema Pharma

Volker Knappertz
BaselTherapeuticsBiotechnologyHealth Care

Description

Noema Pharma, a clinical-stage biotech company focusing on CNS disorders, has appointed Michael Samar as Chief Financial Officer. In addition, Volker Knappertz, M.D., has been appointed as Executive Vice President of Research and Development.

Company Information

Company

Noema Pharma

Location

Basel, Basel-Stadt, Switzerland

About

Noema Pharma is a clinical-stage biotech company advancing a portfolio of transformative, first-in-disease therapeutics targeting neuroscience-based conditions with high unmet need. Noema has four programs currently in active Phase 2 clinical trials evaluating seizures in Tuberous Sclerosis Complex, pain in Trigeminal Neuralgia, Tourette syndrome and vasomotor symptoms plus CNS-mediated symptoms of menopause with readouts expected in 2025. Noema was founded by leading venture capital firm Sofinnova Partners and is supported by current investors including EQT Life Sciences, Forbion, Gilde Healthcare, Invus, Jeito Capital, Polaris Partners and UPMC Enterprises.

Related People

Sign in to view contact details

Sign in to view contact details

Sign in to view contact details

Executive Insights

Based on hiring data
New executive impact window
87% of new executives make significant technology decisions within first 100 days
Budget influence
C-level executives control 73% of technology spending decisions
Transformation catalyst
65% of new senior hires launch digital transformation initiatives
Vendor review timeline
New executives typically review existing vendors within 6 months